Inhibikase Therapeutics, Inc. (IKT) Key Metrics
IKT valuation today
Trailing 12 months · as of October 18, 2026- Market cap
- $230.2M
- Enterprise value
- $212.4M
- P/E (TTM)
- —
- Forward P/E
- —
- PEG ratio
- —
- Price / sales
- 10.4
- Price / book
- 2.0
- EV / EBITDA
- 0.3
- Dividend yield
- —
- Beta
- 0.90
IKT key metrics, 2016–2025
Fiscal year ended December 31, 2025 · U.S. dollarsIKT returns How much profit the business earns on the capital it uses.
Return on equity+16.0 pts
−36.0%
2025 · hover or tap a bar for each year
20162025
Return on assets+14.2 pts
−34.5%
2025 · hover or tap a bar for each year
20162025
Asset turnover
0.00
2025 · hover or tap a bar for each year
20162025
IKT financial health Debt, liquidity and how easily interest is covered.
Net debt−$81.3M
−$178.8M
2025 · hover or tap a bar for each year
20162025
Current ratio−17.7%
21.70
2025 · hover or tap a bar for each year
20162025
IKT efficiency & capital use Working capital cycle and where the cash goes.
Days payables outstanding−4,705 days
6,338 days
2025 · hover or tap a bar for each year
20162025
IKT valuation history
Fiscal year-endToday10-year median
IKT returns on capital
ROEROICROA
Net income (ROE, ROA) or after-tax operating income (ROIC) divided by the average of the opening and closing balance.
IKT debt vs cash
Total debtCash & short-term investments
Debt includes short- and long-term borrowings and, where reported, lease liabilities.
IKT cash returned to shareholders
DividendsBuybacksFree cash flow
IKT price vs earnings per share
Share price at year-endEPS (right axis)
IKT key metrics
2016–2025| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Valuation | ||||||||||
| Market capitalization | $201.5M | — | — | — | — | — | — | — | — | — |
| Enterprise value | $22.8M | — | — | — | — | — | — | — | — | — |
| Price / book | 1.2 | — | — | — | — | — | — | — | — | — |
| Earnings yield | −23.9% | — | — | — | — | — | — | — | — | — |
| Free cash flow yield | −13.8% | — | — | — | — | — | — | — | — | — |
| Share price at fiscal year-end | $2.05 | $3.25 | $1.27 | $3.00 | $8.82 | $41.40 | — | — | — | — |
| Per share | ||||||||||
| Revenue per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Earnings per share | −$0.49 | — | — | — | — | — | — | — | — | — |
| Operating cash flow per share | −$0.28 | — | — | — | — | — | — | — | — | — |
| Free cash flow per share | −$0.28 | — | — | — | — | — | — | — | — | — |
| Cash per share | $1.82 | — | — | — | — | — | — | — | — | — |
| Book value per share | $1.76 | — | — | — | — | — | — | — | — | — |
| Tangible book value per share | $1.76 | — | — | — | — | — | — | — | — | — |
| Capex per share | $0.00 | — | — | — | — | — | — | — | — | — |
| Shares outstanding | 98.3M | — | — | — | — | — | — | — | — | — |
| Returns & profitability | ||||||||||
| Return on equity (ROE) | −36.0% | −52.0% | −118.9% | −60.7% | −61.4% | −108.7% | — | — | — | — |
| Return on assets (ROA) | −34.5% | −48.7% | −96.5% | −53.6% | −51.7% | −38.8% | −398.5% | −137.5% | −194.6% | −385.9% |
| Return on tangible assets | −26.6% | −27.9% | −131.2% | −72.4% | −34.9% | −19.5% | — | −75.6% | −152.9% | −385.9% |
| Free cash flow margin | — | — | — | — | −461.1% | −161.7% | −30.1% | 17.7% | −6.1% | −3.1% |
| Financial health | ||||||||||
| Total debt | — | $110,517 | $622,003 | $351,287 | $248,911 | $318,995 | $373,794 | $233,729 | $459,962 | $328,942 |
| Cash & short-term investments | $178.8M | $97.5M | $13.3M | $23.1M | $40.8M | $14.0M | $18,457 | $379,557 | $16,665 | $12,036 |
| Net debt | −$178.8M | −$97.4M | −$12.6M | −$22.7M | −$40.5M | −$13.6M | $355,337 | −$145,828 | $443,297 | $316,906 |
| Debt / equity | — | 0.00 | 0.06 | 0.02 | 0.01 | 0.03 | — | — | — | — |
| Debt / assets | — | 0.00 | 0.04 | 0.01 | 0.01 | 0.02 | 9.77 | 0.08 | 1.61 | 2.02 |
| Current ratio | 21.70 | 26.37 | 4.13 | 6.59 | 10.47 | 3.13 | 0.01 | 0.35 | 0.11 | 0.05 |
| Quick ratio | 21.70 | 26.37 | 3.81 | 6.29 | 10.45 | 3.13 | 0.01 | 0.35 | 0.11 | 0.05 |
| Interest coverage | — | — | -269.8 | -243.5 | -741.2 | -95.9 | -229.4 | -70.0 | — | — |
| Working capital | $171.8M | $94.7M | $10.8M | $20.7M | $38.4M | $10.1M | −$4.2M | −$2.4M | −$1.5M | −$1.4M |
| Invested capital | −$5.9M | −$2.6M | −$1.7M | −$1.7M | −$2.1M | −$3.9M | −$4.1M | −$923,793 | −$997,711 | −$1.0M |
| Tangible asset value | $172.9M | $94.9M | $11.0M | $21.0M | $38.4M | $9.8M | −$4.5M | −$777,965 | −$1.4M | −$1.4M |
| Net current asset value | $171.8M | $94.7M | $10.7M | $20.5M | $38.4M | $9.8M | −$4.5M | −$2.4M | −$1.5M | −$1.4M |
| Graham net-net per share | $1.73 | — | — | — | — | — | — | — | — | — |
| Capital allocation | ||||||||||
| Dividends paid | — | — | — | — | $77,652 | — | — | — | — | — |
| Share buybacks (net) | — | — | — | — | $77,652 | — | — | — | — | — |
| Capex / revenue | — | — | 5.5% | 197.1% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Capex / operating cash flow | — | — | — | — | — | — | — | 0.0% | — | — |
| Capex / depreciation | 0.22 | 0.00 | 0.08 | 36.18 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-based compensation / revenue | — | — | 192.0% | 371.1% | 49.4% | 82.1% | 128.0% | 15.9% | 14.6% | 32.1% |
| R&D / revenue | — | — | 5,227.8% | 9,749.7% | 366.4% | 128.0% | 227.4% | 90.3% | 85.2% | 87.5% |
| SG&A / revenue | — | — | 2,562.7% | 5,036.5% | 209.9% | 375.6% | 380.2% | 62.3% | — | — |
| Efficiency | ||||||||||
| Days sales outstanding | — | — | 55.9 | 221.8 | 6.5 | 0.0 | — | 29.5 | 21.9 | 25.2 |
| Days of inventory on hand | — | — | 30.0 | 33,243.0 | 3.4 | — | — | — | — | — |
| Days payables outstanding | 6,338.1 | 11,043.5 | 24.1 | 60,832.0 | 45.2 | 555.9 | 139.8 | 65.4 | 81.6 | 186.2 |
| Cash conversion cycle (days) | — | — | 61.7 | -27,367.2 | -35.2 | -555.9 | — | -35.9 | -59.7 | -161.0 |
| Receivables turnover | — | — | 6.53 | 1.65 | 56.30 | — | — | 12.36 | 16.64 | 14.46 |
| Payables turnover | 0.06 | 0.03 | 15.15 | 0.01 | 8.08 | 0.66 | 2.61 | 5.58 | 4.47 | 1.96 |
| Inventory turnover | — | — | 12.19 | 0.01 | 106.16 | — | — | — | — | — |
| Asset turnover | 0.00 | 0.00 | 0.01 | 0.00 | 0.11 | 0.09 | 0.78 | 2.58 | 9.20 | 5.94 |
| Average receivables | — | — | $39,881 | $75,011 | $55,070 | $0 | — | $326,860 | $123,829 | $66,878 |
| Average payables | $1.1M | $794,893 | $898,970 | $1.1M | $1.4M | $1.4M | $977,968 | $653,880 | $392,656 | $431,791 |
| Average inventory | — | — | $1.1M | $612,308 | $107,000 | — | — | — | — | $0 |
| Intangibles / total assets | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
Computed from IKT's annual financial statements (latest annual report filed March 26, 2026) and the closing share price on each fiscal year-end, adjusted for stock splits. Figures in U.S. dollars; data from EODHD. Averages use the opening and closing balance of each year.
IKT valuation and financial ratios
Inhibikase Therapeutics earned a return on equity of −36.0% in fiscal 2025.
See the IKT income statement, the IKT chart for price history, or the IKT stock overview for the latest quote and news.
IKT key metrics FAQ
What is Inhibikase Therapeutics's return on equity?
Inhibikase Therapeutics's return on equity (ROE) was −36.0% in fiscal 2025: net income of -$48.3 million on average shareholders' equity of $133.9 million.
What is Inhibikase Therapeutics's free cash flow yield?
Inhibikase Therapeutics generated -$27.8 million of free cash flow in fiscal 2025, a free cash flow yield of −13.8% on its market value at year-end ($201.5 million).
What is Inhibikase Therapeutics's current ratio?
Inhibikase Therapeutics's current ratio was 21.70 at the end of fiscal 2025: current assets were 21.70 times current liabilities.